Celsion Corp. (CLSN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.22-0.01 (-0.81%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.23
Bid0.00 x
Ask1.25 x 600
Day's Range1.20 - 1.24
52wk Range1.04 - 2.31
1y Target EstN/A
Market Cap31.49M
P/E Ratio (ttm)-1.43
Avg Vol (3m)83,198
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETF’s with exposure to Celsion Corp. : August 19, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Celsion Corp. Here are 5 ETF’s with the largest exposure to CLSN-US. Comparing the performance and risk of Celsion Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
    Capital Cube10 days ago

    Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016

    Categories: Yahoo Finance Get free summary analysis Celsion Corp. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Celsion Corp. – Threshold Pharmaceuticals, Inc., ArQule, Inc., Cerulean Pharma, Inc., Endocyte, Inc., Spectrum Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., ImmunoGen, Inc., Exelixis, Inc. and Keryx Biopharmaceuticals, Inc. (THLD-US, ARQL-US, ... Read more (Read more...)

  • GlobeNewswire13 days ago

    Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update

    Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses. Company to Hold Conference Call on Monday, August 15, 2016 at 11:00 a.m. ...